EDMONTON, April 22 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. ("Quest" or the "Company") is pleased to announce that it will receive generous support from NRC-IRAP towards the development of Quest's Sonodynamic Therapy (SDT) for oncology applications.
Sonodynamic Therapy arises out of the Company's long-term interest in Hypocrellin-based photodynamic therapy for oncology and skin diseases. The Company's lead compound, SL017, with Intense Pulse Light is currently being evaluated for hair removal applications in a 90 patient Phase II clinical trial. A second product, SL052, in combination with laser light activation is in late-stage pre-clinical development for prostate cancer treatment and is scheduled to enter a Phase I clinical trial during the second half of 2008. Both products can also be activated by ultrasound.
SDT involves the administration of non-toxic pharmaceutical agents which may be activated deep within the body, by ultrasound, which is in itself non-toxic. The attractive features of this technology for cancer treatment emerges from the ability to focus the ultrasound energy on malignancy sites buried deep in tissues and to locally activate a preloaded sonosensitizer. The goal of SDT is to provide effective and specific eradication or control of tumors, while minimizing or eliminating toxicity and morbidity to the remainder of the patient.
Financial support of up to $198,362 from NRC/IRAP will help the Company
to obtain proof-of-concept for the use of its proprietary Hypocrellin-based
compounds for Sonodynamic Therapy applications. Technology development will
also include new formulations involving nanoparticles and development of
unique ultrasound transducers. In addition to the financial support, IRAP
will continue to play an advisory role in acquiring complementary
technologies to commercialize SDT-based products. The overall program will
be coordinated by Dr. Gerald Miller, Executive Consultant to the Company
|SOURCE Quest PharmaTech Inc.|
Copyright©2008 PR Newswire.
All rights reserved